Virus-related cancers account for around 20% of all human cancers worldwide, representing a significant portion of the global cancer burden. In particular, at least six human viruses, Epstein–Barr virus (EBV), human papilloma virus (HPV), human T-cell lymphotropic virus (HTLV-1), hepatitis B virus (HBV), hepatitis C virus (HCV), and Kaposi's associated sarcoma virus (KSHV) were reported to cause nasopharyngeal cancer, cervical cancer, adult T-cell leukemia, liver cancer, and Kaposi's sarcoma respectively. Human tumor-associated viruses lead to malignancies with a prolonged latency and deeply participate in critical progress during tumorigenesis and immune escape, including initiation of chronic inflammation, enabling replicative immortality, genome instability and mutation, metabolic reprogramming, tumor immune microenvironment modulation, and immune editing. Although some immune interventions have significantly improved the clinical outcomes, such as HPV vaccines for cervical cancer and chemotherapy for nasopharyngeal cancer, the immune heterogeneity and potential intervention strategy in patients with different virus-related cancers remain largely elusive.
In this Research Topic, we will focus on improving our understanding of viral infection, tumorigenesis, host tumor immune microenvironment, and potential intervention technology in different virus-related tumors. The aim is to collect original research on the immune regulation mechanism, animal models, preclinical investigation, and novel intervention strategies for viral infection-related cancers.
We welcome the submission of Original Research, Review, Mini Review, Case Report, Opinion, and Perspective articles, covering, but not limited to, the following sub-topics:
• Reviews of our understanding of immune regulation and intervention of virus-related cancers.
• Preclinical research that could further our understanding of immune signatures associated with virus-related cancer.
• The use of novel technologies to understand immune heterogeneity contributing to virus-related cancers.
• Translational research by focusing on the identification of new drugs and new approaches for the development of diagnostic and therapeutic modalities for virus-related cancers.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Virus-related cancers account for around 20% of all human cancers worldwide, representing a significant portion of the global cancer burden. In particular, at least six human viruses, Epstein–Barr virus (EBV), human papilloma virus (HPV), human T-cell lymphotropic virus (HTLV-1), hepatitis B virus (HBV), hepatitis C virus (HCV), and Kaposi's associated sarcoma virus (KSHV) were reported to cause nasopharyngeal cancer, cervical cancer, adult T-cell leukemia, liver cancer, and Kaposi's sarcoma respectively. Human tumor-associated viruses lead to malignancies with a prolonged latency and deeply participate in critical progress during tumorigenesis and immune escape, including initiation of chronic inflammation, enabling replicative immortality, genome instability and mutation, metabolic reprogramming, tumor immune microenvironment modulation, and immune editing. Although some immune interventions have significantly improved the clinical outcomes, such as HPV vaccines for cervical cancer and chemotherapy for nasopharyngeal cancer, the immune heterogeneity and potential intervention strategy in patients with different virus-related cancers remain largely elusive.
In this Research Topic, we will focus on improving our understanding of viral infection, tumorigenesis, host tumor immune microenvironment, and potential intervention technology in different virus-related tumors. The aim is to collect original research on the immune regulation mechanism, animal models, preclinical investigation, and novel intervention strategies for viral infection-related cancers.
We welcome the submission of Original Research, Review, Mini Review, Case Report, Opinion, and Perspective articles, covering, but not limited to, the following sub-topics:
• Reviews of our understanding of immune regulation and intervention of virus-related cancers.
• Preclinical research that could further our understanding of immune signatures associated with virus-related cancer.
• The use of novel technologies to understand immune heterogeneity contributing to virus-related cancers.
• Translational research by focusing on the identification of new drugs and new approaches for the development of diagnostic and therapeutic modalities for virus-related cancers.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
